| Literature DB >> 31496695 |
Yanhai Xi1, Tingwang Jiang2, Yinglan Yu3, Jiangmin Yu1, Mintao Xue1, Ning Xu1, Jiankun Wen1, Weiheng Wang1, Hailong He1, Yan Shen3, Daquan Chen4, Xiaojian Ye1, Thomas J Webster5.
Abstract
INTRODUCTION: Curcumin (CUR) is a general ingredient of traditional Chinese medicine, which has potential antitumor effects. However, its use clinically has been limited due to its low aqueous solubility and bioavailability. In order to improve the therapeutic effect of CUR on osteosarcoma (i.e., bone cancer), a multifunctional micelle was developed here by combining active bone accumulating ability with tumor CD44 targeting capacity.Entities:
Keywords: alendronate; curcumin; hyaluronic acid; osteosarcoma
Mesh:
Substances:
Year: 2019 PMID: 31496695 PMCID: PMC6691947 DOI: 10.2147/IJN.S211981
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Schematic representation for the synthesis of (A) hyaluronic acid-octadecanoic acid (HA-C18) and (B) alendronate-hyaluronic acid-octadecanoic acid (ALN-HA-C18).
The orthogonal design factors and levels
| Independent variables | Levels | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| X1: The mass ratio of polymer to drug | 5: 1 | 10: 1 | 15: 1 |
| X2: Type of organic solvent | Ethanol | Acetone | Chloroform |
| X3: Solidification temperature (°C) | 40 | 60 | 80 |
Figure 21H NMR spectrum of (A) hyaluronic acid (HA) and (B) alendronate-hyaluronic acid-octadecanoic acid (ALN-HA-C18).
Figure 3Plots of I1/I3 against the logarithim of the ALN-HA-C18 concentration.
The orthogonal design L9 (34) and resulting values
| Experiments | Variables | Responses | |||
|---|---|---|---|---|---|
| X1: Polymer to drug | X2: Type of organic solvent | X3: Solidification temperature (°C) | Y1: Particle size (nm) | Y2: EE% (%) | |
| 1 | 1 | 1 | 1 | 244.4 | 12.3 |
| 2 | 1 | 2 | 2 | 248.5 | 37.6 |
| 3 | 1 | 3 | 3 | 324.2 | 9.7 |
| 4 | 2 | 1 | 2 | 122.2 | 36.6 |
| 5 | 2 | 2 | 3 | 115.3 | 34.4 |
| 6 | 2 | 3 | 1 | 472.5 | 8.2 |
| 7 | 3 | 1 | 3 | 200.8 | 18.0 |
| 8 | 3 | 2 | 1 | 220.2 | 32.3 |
| 9 | 3 | 3 | 2 | 377 | 10.8 |
| K1 | 272.4 | 189.1 | 312.4 | ||
| K2 | 236.7 | 188.2 | 249.2 | ||
| K3 | 266 | 391.2 | 213.4 | ||
| R | 35.7 | 202.1 | 99 | ||
| K1’ | 19.9 | 22.3 | 17.6 | ||
| K2’ | 26.4 | 34.8 | 28.3 | ||
| K3’ | 20.4 | 16.7 | 20.7 | ||
| R’ | 6.5 | 18.1 | 10.7 | ||
Figure 4The size distribution (A) and transmission electron microscopy (TEM) image (B) of CUR loaded ALN-HA-C18 micelles. (C) In vitro release characteristics of free CUR and CUR loaded ALN-HA-C18 micelles in 1% Tween 80 PBS medium. (D) Binding ratio of CUR, CUR loaded HA-C18 micelles, and CUR loaded ALN-HA-C18 micelles with hydroxyapatite. Data are presented as the mean ± SD (n=3). ***Significant difference between the two groups (***P<0.001).
Figure 5In vitro cytotoxicity of blank ALN-HA-C18 micelles, free CUR, and CUR loaded ALN-HA-C18 micelles against HOB cells (A) and MG-63 osteosarcoma cells (B). Fluorescence microscope images (C) and flow cytometry analysis (D) of MG-63 cells incubated with free C6, C6 loaded ALN-HA-C18 micelles with HA and C6 loaded ALN-HA-C18 micelles. Data are presented as the mean ± SD (n=6). *, ** and *** represent P<0.05, P<0.01 and P<0.001, respectively. The bar is 50 μm.
Figure 6The in vivo antitumor activity of CUR loaded ALN-HA-C18 micelles on osteosarcoma bearing nude mice. (A) Tumor volume changes; and (B) body weight changes. (C) The hematoxylin and eosin (H&E) staining of the heart, liver, spleen, lung and kidney in saline and CUR loaded ALN-HA-C18 micelles group after treatment. Data are presented as the mean ± SD (n=6). *Represents P<0.05. Bars =100 μm.